Logo image of RPTX

REPARE THERAPEUTICS INC (RPTX) Stock Fundamental Analysis

NASDAQ:RPTX - Nasdaq - US7602731025 - Common Stock

1.23  -0.01 (-0.81%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RPTX. RPTX was compared to 572 industry peers in the Biotechnology industry. RPTX has a great financial health rating, but its profitability evaluates not so good. RPTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RPTX has reported negative net income.
RPTX had a negative operating cash flow in the past year.
In the past 5 years RPTX always reported negative net income.
In the past 5 years RPTX reported 4 times negative operating cash flow.
RPTX Yearly Net Income VS EBIT VS OCF VS FCFRPTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

RPTX has a Return On Assets (-36.92%) which is in line with its industry peers.
RPTX's Return On Equity of -44.20% is fine compared to the rest of the industry. RPTX outperforms 69.38% of its industry peers.
Industry RankSector Rank
ROA -36.92%
ROE -44.2%
ROIC N/A
ROA(3y)-24.63%
ROA(5y)-23.07%
ROE(3y)-30.56%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
RPTX Yearly ROA, ROE, ROICRPTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RPTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPTX Yearly Profit, Operating, Gross MarginsRPTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K -40K -50K

More info and screens

7

2. Health

2.1 Basic Checks

RPTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RPTX has been increased compared to 1 year ago.
RPTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RPTX Yearly Shares OutstandingRPTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
RPTX Yearly Total Debt VS Total AssetsRPTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

RPTX has an Altman-Z score of -1.42. This is a bad value and indicates that RPTX is not financially healthy and even has some risk of bankruptcy.
RPTX has a Altman-Z score of -1.42. This is comparable to the rest of the industry: RPTX outperforms 56.28% of its industry peers.
There is no outstanding debt for RPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.42
ROIC/WACCN/A
WACC9.66%
RPTX Yearly LT Debt VS Equity VS FCFRPTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 6.24 indicates that RPTX has no problem at all paying its short term obligations.
The Current ratio of RPTX (6.24) is better than 63.19% of its industry peers.
A Quick Ratio of 6.24 indicates that RPTX has no problem at all paying its short term obligations.
RPTX has a better Quick ratio (6.24) than 63.54% of its industry peers.
Industry RankSector Rank
Current Ratio 6.24
Quick Ratio 6.24
RPTX Yearly Current Assets VS Current LiabilitesRPTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.42% over the past year.
Looking at the last year, RPTX shows a very negative growth in Revenue. The Revenue has decreased by -61.20% in the last year.
The Revenue has been growing by 699.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)13.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)-61.2%
Revenue growth 3Y699.65%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, RPTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.36% on average per year.
The Revenue is expected to decrease by -13.93% on average over the next years. This is quite bad
EPS Next Y1.96%
EPS Next 2Y-15.34%
EPS Next 3Y-0.93%
EPS Next 5Y13.36%
Revenue Next Year-8.54%
Revenue Next 2Y-66.9%
Revenue Next 3Y-32.03%
Revenue Next 5Y-13.93%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RPTX Yearly Revenue VS EstimatesRPTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
RPTX Yearly EPS VS EstimatesRPTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RPTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RPTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPTX Price Earnings VS Forward Price EarningsRPTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPTX Per share dataRPTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.34%
EPS Next 3Y-0.93%

More info and screens

0

5. Dividend

5.1 Amount

RPTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REPARE THERAPEUTICS INC

NASDAQ:RPTX (1/22/2025, 11:41:04 AM)

1.23

-0.01 (-0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners79.17%
Inst Owner Change0.03%
Ins Owners1.09%
Ins Owner Change0%
Market Cap52.29M
Analysts80
Price Target8.77 (613.01%)
Short Float %3.37%
Short Ratio2.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.28%
Min EPS beat(2)-83.19%
Max EPS beat(2)48.63%
EPS beat(4)2
Avg EPS beat(4)7.4%
Min EPS beat(4)-83.19%
Max EPS beat(4)64.81%
EPS beat(8)4
Avg EPS beat(8)39.51%
EPS beat(12)5
Avg EPS beat(12)23.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-49.44%
Min Revenue beat(2)-66.45%
Max Revenue beat(2)-32.43%
Revenue beat(4)1
Avg Revenue beat(4)44.51%
Min Revenue beat(4)-66.45%
Max Revenue beat(4)285.98%
Revenue beat(8)3
Avg Revenue beat(8)878.58%
Revenue beat(12)5
Avg Revenue beat(12)593.82%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-31.2%
PT rev (3m)-37.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)5.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-1.26%
Revenue NY rev (3m)-4.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.02
P/FCF N/A
P/OCF N/A
P/B 0.25
P/tB 0.25
EV/EBITDA N/A
EPS(TTM)-2
EYN/A
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)-3.04
FCFYN/A
OCF(TTM)-2.99
OCFYN/A
SpS1.2
BVpS4.99
TBVpS4.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.92%
ROE -44.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.63%
ROA(5y)-23.07%
ROE(3y)-30.56%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 99.33%
Cap/Sales 3.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.24
Quick Ratio 6.24
Altman-Z -1.42
F-Score2
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)81.53%
Cap/Depr(5y)141.32%
Cap/Sales(3y)8.83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y1.96%
EPS Next 2Y-15.34%
EPS Next 3Y-0.93%
EPS Next 5Y13.36%
Revenue 1Y (TTM)-61.2%
Revenue growth 3Y699.65%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-8.54%
Revenue Next 2Y-66.9%
Revenue Next 3Y-32.03%
Revenue Next 5Y-13.93%
EBIT growth 1Y-490.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.24%
EBIT Next 3Y-8.44%
EBIT Next 5YN/A
FCF growth 1Y-46005.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39836.9%
OCF growth 3YN/A
OCF growth 5YN/A